89 results
424B5
OVID
Ovid Therapeutics Inc
15 Nov 23
Prospectus supplement for primary offering
4:11pm
, 2022 and 2021, and for each of the years in the two-year period ended December 31, 2022, and management’s assessment of the effectiveness of internal
8-K
EX-99.1
8x0lj
3 Nov 23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
8:10am
8-K
EX-99.1
sj2fvbb0
27 Apr 23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4:43pm